ATE224724T1 - Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin- rezeptor interaktion - Google Patents

Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin- rezeptor interaktion

Info

Publication number
ATE224724T1
ATE224724T1 AT97954430T AT97954430T ATE224724T1 AT E224724 T1 ATE224724 T1 AT E224724T1 AT 97954430 T AT97954430 T AT 97954430T AT 97954430 T AT97954430 T AT 97954430T AT E224724 T1 ATE224724 T1 AT E224724T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
containing peptides
receptor interaction
immunoglobulin receptor
Prior art date
Application number
AT97954430T
Other languages
English (en)
Inventor
Giorgio Fassina
Falco Sandro De
Original Assignee
Tecnogen Scpa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnogen Scpa filed Critical Tecnogen Scpa
Application granted granted Critical
Publication of ATE224724T1 publication Critical patent/ATE224724T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97954430T 1996-12-16 1997-12-11 Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin- rezeptor interaktion ATE224724T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96MI002628A ITMI962628A1 (it) 1996-12-16 1996-12-16 Composizione farmaceutica
PCT/EP1997/007143 WO1998026794A1 (en) 1996-12-16 1997-12-11 Pharmaceutical composition containing an inhibitor of immunoglobulin-receptor interaction

Publications (1)

Publication Number Publication Date
ATE224724T1 true ATE224724T1 (de) 2002-10-15

Family

ID=11375401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97954430T ATE224724T1 (de) 1996-12-16 1997-12-11 Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin- rezeptor interaktion

Country Status (13)

Country Link
US (1) US6426401B1 (de)
EP (1) EP0948345B1 (de)
JP (1) JP4071830B2 (de)
KR (1) KR100502074B1 (de)
CN (1) CN1216637C (de)
AT (1) ATE224724T1 (de)
AU (1) AU5858398A (de)
CA (1) CA2275213A1 (de)
DE (1) DE69715910T2 (de)
EA (1) EA001468B1 (de)
ES (1) ES2183237T3 (de)
IT (1) ITMI962628A1 (de)
WO (1) WO1998026794A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
WO2005086947A2 (en) 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
ITMI20071119A1 (it) 2007-06-01 2008-12-02 Tecnogen Spa Nuovi ligandi sintetici per immunoglobuline e composizioni farmaceutiche che li comprendono
MX2011000647A (es) 2008-07-18 2011-09-29 Trinity Therapeutics Inc Metodos para el tratamiento de infecciones por fiebre de dengue mediadas por el sistema inmunitario e intensificacion dependiente de anticuerpos de infecciones por fiebre de dengue, incluyendo fiebre hemorragica de dengue y sindrome de choque de deng
US10591480B2 (en) 2016-06-06 2020-03-17 Medizinische Universität Wien Method for the detection of an IgM antibody specific for a flavivirus in a sample

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents
WO1986001211A1 (en) * 1984-08-10 1986-02-27 MERCK Patent Gesellschaft mit beschränkter Haftung Immunotherapeutic polypeptide agents
FR2655269B1 (fr) * 1989-12-01 1994-02-11 Curie Universite Pierre Marie Proteines empechant l'interaction entre un fragment fc d'une immunoglobuline et son recepteur et utilisation en therapeutique, notamment dans le traitement des affections liees aux virus hiv.
AU3002695A (en) * 1994-07-08 1996-02-09 King's College Ige antagonists
ATE185147T1 (de) * 1995-06-21 1999-10-15 Tecnogen Scpa Peptidliganden für die konstante region von immunoglobulinen

Also Published As

Publication number Publication date
CA2275213A1 (en) 1998-06-25
KR20000057634A (ko) 2000-09-25
US6426401B1 (en) 2002-07-30
JP2001506994A (ja) 2001-05-29
EP0948345B1 (de) 2002-09-25
EA001468B1 (ru) 2001-04-23
EA199900551A1 (ru) 2000-02-28
ES2183237T3 (es) 2003-03-16
DE69715910D1 (de) 2002-10-31
JP4071830B2 (ja) 2008-04-02
CN1216637C (zh) 2005-08-31
WO1998026794A1 (en) 1998-06-25
KR100502074B1 (ko) 2005-07-25
DE69715910T2 (de) 2003-05-22
AU5858398A (en) 1998-07-15
EP0948345A1 (de) 1999-10-13
CN1240357A (zh) 2000-01-05
ITMI962628A0 (it) 1996-12-16
ITMI962628A1 (it) 1998-06-16

Similar Documents

Publication Publication Date Title
ES2107357A1 (es) Sales de peptidos con poliesteres carboxi-terminados.
EP1093372A4 (de) Aminosäureverbindungen, pharmazeutische zusammensetzungen damit und verfahren zur hemmung von a(b)-amyloid-peptid freisetzung und/oder deren synthese durch verwendung dieser verbindungen
HU9302762D0 (en) N-sulfonyl-2-oxoindole derivatives being effective on vasopressin and/or oxitocin receptors
ATE295346T1 (de) N-(aryl/heteroarylacetyl)aminosäureester, diese enthaltende pharmazeutische zusammensetzungen und methoden zur inhibierung der beta- amyloidfreisetzung und/oder deren synthese unter verwendung dieser verbindungen
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
EP0254080A3 (en) Malonic acid derivatives and methods for their synthesis
ATE184022T1 (de) Neuropeptide y antagoniste
SI1078001T1 (sl) Il-6-antagonisticni peptidi
KR930702386A (ko) 노나펩티드 봄베신 길항제
CS202568B2 (en) Process for preparing polypeptides
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE69715910D1 (de) Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin-rezeptor interaktion
NO971997D0 (no) Bruk av immunmodulerende midler
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
ATE185147T1 (de) Peptidliganden für die konstante region von immunoglobulinen
DE69319733D1 (de) In der konformation beschränkte peptid analoge als wirkstoff gegen plättchenaggregation
RU93004822A (ru) Пептиды, способ их получения, содержащее их лекарственное средство
NZ511618A (en) Kininogen fragment 2 peptides with the formula of at least X-His-Lys-X-Lys-X
Lundquist et al. Synthesis and Human Neurotensin Receptor Binding Activities of Neurotensin (8− 13) Analogues Containing Position 8 α-Azido-N-alkylated Derivatives of Ornithine, Lysine, and Homolysine
ATE30919T1 (de) Magensekretion hemmende peptidderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
KR970701732A (ko) 펩신 방출을 억제하기 위한 펩티드(Peptides Inhibiting the Release of Pepsin)
DK0410278T3 (da) Reninhæmmende aminooligohydroxyderivater
KR930017874A (ko) 포화 질소 헤테로사이클의 유도체

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0948345

Country of ref document: EP

REN Ceased due to non-payment of the annual fee